Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (8): 789-793.doi: 10.35541/cjd.20201200

• Reviews • Previous Articles     Next Articles

Application of biologic agents in the treatment of bullous pemphigoid

Zhou Tong, Geng Songmei   

  1. Department of Dermatology, The Second Affiliated Hospital of Xi′an Jiaotong University, Xi′an 710004, China
  • Received:2020-12-15 Revised:2021-08-31 Online:2023-08-15 Published:2023-08-07
  • Contact: Geng Songmei

Abstract: 【Abstract】 In recent years, new therapeutic targets for bullous pemphigoid (BP) have continued to emerge, and new biologic agents targeting pathogenic antibodies, complements, T helper type 2 (Th2) and Th17 cytokines in BP have also successively entered clinical trials, e.g., the CD20-targeting antibody rituximab and the IgE-targeting antibody omalizumab have been applied in clinical practice and have benefited some patients with refractory BP. This review summarizes the literature and clinical trials related to biologic agents as the treatment strategy for BP, analyzes and discusses clinical application of new biological agents in BP, in order to provide new ideas for the treatment of refractory BP.

Key words: Pemphigoid, bullous, Biologic agent, Treatment, Clinical trial, Rituximab, Omalizumab